Cover Image

Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects

Abstract Bersiporocin, a novel first‐in‐class prolyl‐tRNA synthetase (PRS) inhibitor currently under clinical development, was shown to exert an antifibrotic effect through the downregulation of collagen synthesis in various pulmonary fibrosis models. The aim of this first‐in‐human, randomized, doub...

Full description

Saved in:

Bibliographic Details
Main Authors:	Min Young Park (Author), Sungyeun Bae (Author), Jung A Heo (Author), Mihee Park (Author), YuKyung Kim (Author), Jumi Han (Author), In‐Jin Jang (Author), Kyung‐Sang Yu (Author), Jaeseong Oh (Author)
Format:	Book
Published:	Wiley, 2023-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

No drug-drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants
by: Wonsuk Shin, et al.
Published: (2024)

Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration
by: Sungyeun Bae, et al.
Published: (2023)

Glutamyl-Prolyl-tRNA Synthetase Regulates Epithelial Expression of Mesenchymal Markers and Extracellular Matrix Proteins: Implications for Idiopathic Pulmonary Fibrosis
by: Dae-Geun Song, et al.
Published: (2018)

The regulatory roles of aminoacyl-tRNA synthetase in cardiovascular disease
by: Yulin Zou, et al.
Published: (2021)

Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study
by: Joo Young Na, et al.
Published: (2022)

Semimechanistic pharmacokinetic-pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy
by: Soyoung Lee, et al.
Published: (2023)

A Drosophila model for mito-nuclear diseases generated by an incompatible interaction between tRNA and tRNA synthetase
by: Marissa A. Holmbeck, et al.
Published: (2015)

Mutation in methionyl-tRNA synthetase 1 causing pulmonary alveolar proteinosis
by: Manoj Madhusudan, et al.
Published: (2023)

Synthesis and Biological Evaluation of Lipophilic Nucleoside Analogues as Inhibitors of Aminoacyl-tRNA Synthetases
by: Manesh Nautiyal, et al.
Published: (2019)

Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers
by: Woo Kyung Chung, et al.
Published: (2023)

Targeting tRNA-synthetase interactions towards novel therapeutic discovery against eukaryotic pathogens.
by: Paul Kelly, et al.
Published: (2020)

Phenylalanyl-tRNA synthetase deficiency caused by biallelic variants in FARSA gene and literature review
by: Ruolan Guo, et al.
Published: (2023)

Identifying potential natural inhibitors of Brucella melitensis Methionyl-tRNA synthetase through an in-silico approach.
by: Adekunle Babajide Rowaiye, et al.
Published: (2022)

Glycyl tRNA Synthetase (GARS) Gene Variant Causes Distal Hereditary Motor Neuropathy V
by: Peter Chung, et al.
Published: (2018)

Leucyl-tRNA Synthetase Inhibitor, D-Norvaline, in Combination with Oxacillin, Is Effective against Methicillin-Resistant <i>Staphylococcus aureus</i>
by: Hong-Ju Lee, et al.
Published: (2022)

In Vitro Evaluation of Drug-Drug Interaction Potential of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor
by: Afshin Shafiee, et al.
Published: (2024)

Antioxidant activity and antibacterial evaluation of new thiazolin-4-one derivatives as potential tryptophanyl-tRNA synthetase inhibitors
by: Anca Stana, et al.
Published: (2019)

Genetic manipulation of Leishmania donovani threonyl tRNA synthetase facilitates its exploration as a potential therapeutic target.
by: Sanya Chadha, et al.
Published: (2018)

An anti-tuberculosis compound screen using a zebrafish infection model identifies an aspartyl-tRNA synthetase inhibitor
by: Eva Habjan, et al.
Published: (2021)

Entamoeba lysyl-tRNA synthetase contains a cytokine-like domain with chemokine activity towards human endothelial cells.
by: Manuel Castro de Moura, et al.
Published: (2011)

Correction: Entamoeba lysyl-tRNA Synthetase Contains a Cytokine-Like Domain with Chemokine Activity towards Human Endothelial Cells.
by: Manuel Castro de Moura, et al.
Published: (2024)

Structures of Trypanosoma brucei methionyl-tRNA synthetase with urea-based inhibitors provide guidance for drug design against sleeping sickness.
by: Cho Yeow Koh, et al.
Published: (2014)

Protein Translation Enzyme lysyl-tRNA Synthetase Presents a New Target for Drug Development against Causative Agents of Loiasis and Schistosomiasis.
by: Arvind Sharma, et al.
Published: (2016)

Exploring <i>Proteus mirabilis</i> Methionine tRNA Synthetase Active Site: Homology Model Construction, Molecular Dynamics, Pharmacophore and Docking Validation
by: Samar S. Elbaramawi, et al.
Published: (2023)

A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects
by: Park SI, et al.
Published: (2015)

Epetraborole, a leucyl-tRNA synthetase inhibitor, demonstrates murine efficacy, enhancing the in vivo activity of ceftazidime against Burkholderia pseudomallei, the causative agent of melioidosis.
by: Jason E Cummings, et al.
Published: (2023)

A phase I study to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profiles of ocular GLH8NDE in healthy male adults
by: Jihyun Jung, et al.
Published: (2022)

Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
by: Yoon S, et al.
Published: (2015)

Single‐dose of LC51‐0255, a selective S1P1 receptor modulator, showed dose‐dependent and reversible reduction of absolute lymphocyte count in humans
by: Sang Won Lee, et al.
Published: (2022)

Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects
by: Inyoung Hwang, et al.
Published: (2022)

A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects
by: Xu Jiang, et al.
Published: (2024)

Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment resistance
by: Yue Zhang, et al.
Published: (2020)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
by: Jie Lun, et al.
Published: (2023)

Feasibility study for a fully decentralized clinical trial in participants with functional constipation symptoms
by: Ki Young Huh, et al.
Published: (2023)

Fatty acid synthetase expression in triple-negative breast cancer
by: Jin Hee Park, et al.
Published: (2022)

Editorial: Peptidyl-Prolyl Isomerases in Human Pathologies
by: Tiziano Tuccinardi, et al.
Published: (2019)

Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
by: Yu-Hsiang Chou, et al.
Published: (2023)

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
by: Jiang X, et al.
Published: (2023)

Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers
by: Chan Zou, et al.
Published: (2019)

Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects
by: JungJin Oh, et al.
Published: (2023)